Reviva Pharmaceuticals (RVPH) Competitors

$0.35 -0.44 (-55.73%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$0.35 0.00 (-0.60%)

As of 05/13/2026 07:59 PM Eastern

RVPH vs. SCYX, MIRA, ZYBT, ELUT, and ATHE

Should you buy Reviva Pharmaceuticals stock or one of its competitors? MarketBeat compares Reviva Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Reviva Pharmaceuticals include SCYNEXIS (SCYX), MIRA Pharmaceuticals (MIRA), Zhengye Biotechnology (ZYBT), Elutia (ELUT), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical products" industry.

How does Reviva Pharmaceuticals compare to SCYNEXIS?

Reviva Pharmaceuticals (NASDAQ:RVPH) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Reviva Pharmaceuticals presently has a consensus target price of $66.67, indicating a potential upside of 18,834.01%. SCYNEXIS has a consensus target price of $3.00, indicating a potential upside of 294.32%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Reviva Pharmaceuticals is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Reviva Pharmaceuticals has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-959.78%	-162.27%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Reviva Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

SCYNEXIS has higher revenue and earnings than Reviva Pharmaceuticals. SCYNEXIS is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$9.20	N/A
SCYNEXIS	$20.60M	1.65	-$8.61M	-$0.48	N/A

In the previous week, SCYNEXIS had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 5 mentions for SCYNEXIS and 4 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 1.22 beat SCYNEXIS's score of -0.42 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 4.9% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Reviva Pharmaceuticals beats SCYNEXIS on 8 of the 15 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to MIRA Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$9.20	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.53	N/A

MIRA Pharmaceuticals' return on equity of -210.90% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-959.78%	-162.27%
MIRA Pharmaceuticals	N/A	-210.90%	-198.94%

Reviva Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 4 mentions for Reviva Pharmaceuticals and 2 mentions for MIRA Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 1.22 beat MIRA Pharmaceuticals' score of 0.65 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MIRA Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Reviva Pharmaceuticals presently has a consensus target price of $66.67, indicating a potential upside of 18,834.01%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Reviva Pharmaceuticals is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Reviva Pharmaceuticals beats MIRA Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Zhengye Biotechnology has higher revenue and earnings than Reviva Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	2.73	-$9.98M	N/A	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$9.20	N/A

Zhengye Biotechnology's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Reviva Pharmaceuticals	N/A	-959.78%	-162.27%

Zhengye Biotechnology has a beta of -2.47, indicating that its share price is 347% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 4 mentions for Reviva Pharmaceuticals and 2 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.44 beat Reviva Pharmaceuticals' score of 1.22 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Zhengye Biotechnology	Positive
Reviva Pharmaceuticals	Positive

Reviva Pharmaceuticals has a consensus target price of $66.67, suggesting a potential upside of 18,834.01%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Reviva Pharmaceuticals beats Zhengye Biotechnology on 7 of the 12 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Elutia?

Elutia (NASDAQ:ELUT) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Elutia currently has a consensus price target of $6.00, suggesting a potential upside of 471.43%. Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 18,834.01%. Given Reviva Pharmaceuticals' higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Elutia has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

74.0% of Elutia shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 27.6% of Elutia shares are held by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Elutia has higher revenue and earnings than Reviva Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.65	$53.38M	$0.82	1.28
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$9.20	N/A

Elutia has a net margin of 282.63% compared to Reviva Pharmaceuticals' net margin of 0.00%. Elutia's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	282.63%	N/A	-49.57%
Reviva Pharmaceuticals	N/A	-959.78%	-162.27%

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than Elutia. MarketBeat recorded 4 mentions for Reviva Pharmaceuticals and 2 mentions for Elutia. Elutia's average media sentiment score of 1.24 beat Reviva Pharmaceuticals' score of 1.22 indicating that Elutia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elutia beats Reviva Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$9.20	N/A

Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 18,834.01%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alterity Therapeutics' return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Reviva Pharmaceuticals	N/A	-959.78%	-162.27%

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for Reviva Pharmaceuticals and 3 mentions for Alterity Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 1.22 beat Alterity Therapeutics' score of 0.62 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Alterity Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Summary

Reviva Pharmaceuticals beats Alterity Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Reviva Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVPH vs. The Competition

Export

Metric	Reviva Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.19M	$3.04B	$6.30B	$12.20B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-0.04	18.86	21.03	25.58
Price / Sales	N/A	289.31	548.94	78.80
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	0.24	4.35	9.84	6.66
Net Income	-$19.86M	$72.19M	$3.55B	$333.63M
7 Day Performance	-59.17%	-1.05%	-0.52%	-0.12%
1 Month Performance	-58.89%	-0.02%	1.21%	3.93%
1 Year Performance	-97.77%	46.31%	41.24%	36.07%

Reviva Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVPH Reviva Pharmaceuticals	3.2749 of 5 stars	$0.35 -55.7%	$66.67 +18,834.0%	-97.9%	$10.19M	N/A	N/A	5	News Coverage Positive News Earnings Report Upcoming Earnings Gap Down High Trading Volume
SCYX SCYNEXIS	1.8607 of 5 stars	$0.98 -0.6%	$3.00 +204.8%	-21.2%	$44.23M	$20.60M	N/A	60	News Coverage Earnings Report Upcoming Earnings Short Interest Increase Gap Down
MIRA MIRA Pharmaceuticals	1.0007 of 5 stars	$1.03 -1.0%	N/A	-17.7%	$43.70M	N/A	N/A	2	News Coverage Positive News Gap Down
ZYBT Zhengye Biotechnology	1.0903 of 5 stars	$0.96 +4.0%	N/A	-87.1%	$43.60M	$16.64M	N/A	278	Positive News Short Interest Decrease
ELUT Elutia	3.4467 of 5 stars	$1.01 flat	$6.00 +494.1%	-44.7%	$43.21M	$12.29M	1.23	180	News Coverage Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVPH) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. SCYX, MIRA, ZYBT, ELUT, and ATHE

How does Reviva Pharmaceuticals compare to SCYNEXIS?

Summary

How does Reviva Pharmaceuticals compare to MIRA Pharmaceuticals?

Summary

How does Reviva Pharmaceuticals compare to Zhengye Biotechnology?

Summary

How does Reviva Pharmaceuticals compare to Elutia?

Summary

How does Reviva Pharmaceuticals compare to Alterity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. SCYX, MIRA, ZYBT, ELUT, and ATHE

How does Reviva Pharmaceuticals compare to SCYNEXIS?

Do analysts prefer RVPH or SCYX?

Is RVPH or SCYX more profitable?

Which has more risk & volatility, RVPH or SCYX?

Which has stronger valuation and earnings, RVPH or SCYX?

Does the media refer more to RVPH or SCYX?

Do insiders & institutionals have more ownership in RVPH or SCYX?

Summary

How does Reviva Pharmaceuticals compare to MIRA Pharmaceuticals?

Which has better valuation and earnings, RVPH or MIRA?

Is RVPH or MIRA more profitable?

Which has more volatility & risk, RVPH or MIRA?

Does the media prefer RVPH or MIRA?

Do analysts rate RVPH or MIRA?

Do insiders and institutionals have more ownership in RVPH or MIRA?

Summary

How does Reviva Pharmaceuticals compare to Zhengye Biotechnology?

Which has stronger earnings & valuation, ZYBT or RVPH?

Is ZYBT or RVPH more profitable?

Which has more risk and volatility, ZYBT or RVPH?

Does the media favor ZYBT or RVPH?

Do analysts prefer ZYBT or RVPH?

Do institutionals and insiders hold more shares of ZYBT or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Elutia?

Do analysts prefer ELUT or RVPH?

Which has more risk & volatility, ELUT or RVPH?

Do insiders & institutionals hold more shares of ELUT or RVPH?

Which has higher earnings and valuation, ELUT or RVPH?

Is ELUT or RVPH more profitable?

Does the media refer more to ELUT or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Alterity Therapeutics?

Which has preferable valuation & earnings, ATHE or RVPH?

Do analysts recommend ATHE or RVPH?

Is ATHE or RVPH more profitable?

Does the media prefer ATHE or RVPH?

Do insiders and institutionals hold more shares of ATHE or RVPH?

Which has more risk & volatility, ATHE or RVPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools